Effects of Telmisartan and Losartan on Left Ventricular Mass in Mild-to-Moderate Hypertension

Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging

“…In the present study, the relative LV wall thickness and LV mass index were significantly decreased 1 year after telmisartan administration (phase II). Previous studies [10,31,32] also indicated that this agent markedly reduced LV hypertrophy compared with other antihypertensive agents. A meta-analysis emphasized that all antihypertensive agents did not a 0 , peak atrial systolic mitral annular motion velocity; E/e 0 , ratio of peak early diastolic transmitral flow velocity to e 0 ; e 0 , peak early diastolic mitral annular motion velocity; HT, hypertension; LV, left ventricle; s 0 , peak systolic mitral annular motion velocity.…”

A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients

“…those who have not had any previous episodes of AF, and those with paroxysmal or persistent AF who either do not need any antiarrhythmic therapy, or those with persistent AF who do require anti-arrhythmic therapy to maintain sinus rhythm following cardioversion). [16][17][18][19] Telmisartan has the longest half-life of any ARB (approximately 24 hours) 20 and has been shown to reduce left ventricular hypertrophy (LVH) in clinical studies of hypertensive patients, [21][22][23][24] as well as in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant subjects with cardiovascular Disease (TRANSCEND) cardiovascular (CV) outcomes, although no reduction in new-onset AF was found. [25][26][27] The purpose of the present study was to assess the efficacy of an antihypertensive therapeutic dose of telmisartan (80 mg once daily) as compared with that of the β-blocker carvedilol (25 mg once daily), which has been shown to have clinically important anti-arrhythmic properties, [28][29][30][31][32] for the prevention of AF recurrence in a population of hypertensive patients with a recent history of AF and who were in sinus rhythm and who did not require anti-arrhythmic therapy.…”

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study

“…11 Preclinical studies suggest that telmisartan is highly effective in reducing LVH, [12][13][14][15] and preliminary observations provide evidence for the clinical efficacy of telmisartan in the treatment of LVH at doses that confer effective blood pressure control. 16,17 The purpose of the present study was to compare the effect of the standard therapeutic dose of telmisartan 80 mg with that of the thiazide diuretic hydrochlorothiazide (HCTZ) 25 mg on blood pressure, LVM and tolerability in hypertensive subjects after 12 months of treatment. Clinical studies have shown that, in the long term, HCTZ in addition to reducing blood pressure brings about LVH regression in hypertensive patients.…”